U.K. health authorities have run similar surveys over the past four years, but this is the first time it will capture data from schools.
Novartis has brought its job-cutting sword to the U.K., with plans to shutter an R&D site in Horsham. Up to 371 jobs are expected to disappear there. But that's not all. The Swiss drugmaker also plans to shed as many as 72 marketing and sales jobs.
U.K. officials are finally taking the wraps off their new drug-pricing plan. The pharma industry has been waiting for the update to go public--but branded drugmakers are likely to wish they could wait longer. Under the new 5-year agreement, drugmakers will suffer new spending caps beginning next year.
Plenty of drugmakers have grumbled about the U.K.'s cost-effectiveness gatekeepers. The National Institute for Health and Care Excellence does routinely reject new drugs, particularly unless--and until--their makers offer price breaks. But until now, no major drugmaker has threatened to stop investing in Britain unless NICE changes its game.
The company says that it will offer its new cleanroom as a "blank canvas" to potential clients who want to design the process they think will get them what they want. The "bold" move, as the company calls it, is to make its capabilities available to companies that "have a more complex process and sterile product manufacturing need that doesn't fit into the traditional CMO mold," said Dianne Sharp, managing director at SCM Pharma.
The facility will manufacture products for clinical trials and can handle non-sterile dosage forms such as solids, liquids, semi-solids and inhaled products.
The U.K.'s Medicines and Healthcare Products Regulatory Agency (MHRA) last week placed a ban on products from a Wockhardt plant in India because of manufacturing problems, and this week the MHRA clarified that the ban prevents the drugmaker from exporting from that plant to any country in the EU.
Sanofi's closure of a major U.K. facility marks another setback for life sciences employment in the country, and there are no guarantees that workers can find jobs at the new companies that could inhabit the facilities of their former employers.
The U.K. has acknowledged what drugmakers have been warning of for months: There could be a shortage of ingredients if it doesn't give a little on the European Union's July 2 deadline for requiring imported APIs be certified as meeting EU standards.
How much is a generic drug worth to a payer? More than £350 million, for the U.K.'s National Health Service anyway. That's how much it saved during the first 12 months after Pfizer's Lipitor went off patent, the generic industry's trade association says.